Tyrx (Monmouth Junction, NJ) a commercial-stage drug:device combo company focused on a dissolving antibacterial biocompatible mesh envelope to house implanted devices such as pacemakers and defibrillators, closed a $16M Series C financing. Participants include HLM Venture Partners, Clarus Ventures and Pappas Ventures.